Literature DB >> 3939037

Inhibition of nucleoside diphosphate reductase by hydroxybenzohydroxamic acid derivatives.

H L Elford, B van't Riet.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3939037     DOI： 10.1016/0163-7258(85)90031-2

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN： 0163-7258            Impact factor:   12.310


× No keyword cloud information.
  10 in total

1.  Metabolic enzyme considerations in cancer therapy.

Authors:  Amit K Jain; Sweta Jain; A C Rana
Journal:  Malays J Med Sci       Date:  2007-01

2.  3,4-Dihydroxy-benzohydroxamic acid (Didox) suppresses pro-inflammatory profiles and oxidative stress in TLR4-activated RAW264.7 murine macrophages.

Authors:  Thabe M Matsebatlela; Amy L Anderson; Vincent S Gallicchio; Howard Elford; Charles D Rice
Journal:  Chem Biol Interact       Date:  2015-04-02       Impact factor: 5.192

3.  Antimalarial activities of polyhydroxyphenyl and hydroxamic acid derivatives.

Authors:  K P Holland; H L Elford; V Bracchi; C G Annis; S M Schuster; D Chakrabarti
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

4.  Synthesis and testing of new antileukemic Schiff bases of N-hydroxy-N'-aminoguanidine against CCRF-CEM/0 human leukemia cells in vitro and synergism studies with cytarabine (Ara-C).

Authors:  P B Koneru; E J Lien; V I Avramis
Journal:  Pharm Res       Date:  1993-04       Impact factor: 4.200

5.  Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase.

Authors:  T Szekeres; K Gharehbaghi; M Fritzer; M Woody; A Srivastava; B van't Riet; H N Jayaram; H L Elford
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 6.  Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity.

Authors:  Jing Zhang; Xiaohai Cui; Yan Yan; Min Li; Ya Yang; Jiansheng Wang; Jia Zhang
Journal:  Am J Transl Res       Date:  2016-07-15       Impact factor: 4.060

7.  A phase 1 and pharmacokinetic study of didox: a ribonucleotide reductase inhibitor.

Authors:  D Veale; J Carmichael; B M Cantwell; H L Elford; R Blackie; D J Kerr; S B Kaye; A L Harris
Journal:  Br J Cancer       Date:  1988-07       Impact factor: 7.640

8.  A phase I and pharmacokinetic study of didox administered by 36 hour infusion. The Cancer Research Campaign Phase I/II Clinical Trials Committee.

Authors:  J Carmichael; B M Cantwell; K A Mannix; D Veale; H L Elford; R Blackie; D J Kerr; S B Kaye; A L Harris
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

9.  Phase II trial of didox in advanced breast cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee.

Authors:  R D Rubens; S B Kaye; M Soukop; C J Williams; M H Brampton; A L Harris
Journal:  Br J Cancer       Date:  1991-12       Impact factor: 7.640

10.  The Antitumor Didox Acts as an Iron Chelator in Hepatocellular Carcinoma Cells.

Authors:  Michela Asperti; Luca Cantamessa; Simone Ghidinelli; Magdalena Gryzik; Andrea Denardo; Arianna Giacomini; Giovanna Longhi; Alessandro Fanzani; Paolo Arosio; Maura Poli
Journal:  Pharmaceuticals (Basel)       Date:  2019-09-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.